Valuation: HitGen Inc.

Market Cap 11.06B 1.64B 1.42B 1.33B 1.22B 2.3B 156B 2.33B 15.62B 6.13B 77.83B 6.15B 6.02B 261B P/E 2026 *
81.2x
P/E 2027 * 63.5x
Enterprise Value 11.06B 1.64B 1.42B 1.33B 1.22B 2.3B 156B 2.33B 15.62B 6.13B 77.83B 6.15B 6.02B 261B EV / Sales 2026 *
17.3x
EV / Sales 2027 * 14.2x
Free-Float
50.43%
Yield 2026 *
0.31%
Yield 2027 * 0.54%
1 day+4.98%
1 week-0.07%
1 month-14.01%
3 months-3.50%
6 months-11.25%
Current year+17.74%
1 week 26.27
Extreme 26.27
29.78
1 month 25.85
Extreme 25.85
38.67
Current year 22.42
Extreme 22.42
42.98
1 year 21.46
Extreme 21.46
42.98
3 years 8.35
Extreme 8.35
42.98
5 years 8.35
Extreme 8.35
42.98
10 years 8.35
Extreme 8.35
61.99
Manager TitleAgeSince
Chief Executive Officer 63 2012-05-31
Director of Finance/CFO 56 2023-04-26
Investor Relations Contact 38 2019-06-30
Director TitleAgeSince
Chairman 63 2012-05-31
Director/Board Member 73 2012-01-31
Director/Board Member 65 2019-03-23
Change 5-day change 1-year change 3-year change Capi.($)
+4.98%-0.07%+17.79%+77.33% 1.64B
+2.35%+2.74%+33.41%+79.20% 56.54B
-0.21%-7.38%+25.34%+63.02% 53.6B
-2.44%+1.40%-15.74%-16.80% 22.91B
-2.85%-7.78%-8.09%+346.36% 21.37B
+2.49%-0.92%+20.31%-12.15% 20.27B
+0.79%-1.06%+29.29%-33.32% 17.56B
+0.58%-5.88%+16.30%+540.37% 14.75B
-5.25%-4.23%+46.41%+169.05% 13.33B
+3.41%-6.61%+163.08%+280.43% 13.53B
Average +0.39%-4.10%+32.81%+149.35% 23.55B
Weighted average by Cap. +0.26%-2.99%+28.60%+119.68%

Financials

2026 *2027 *
Net sales 638M 94.44M 82.1M 76.41M 70.16M 132M 9.02B 135M 901M 354M 4.49B 355M 347M 15.05B 781M 116M 101M 93.56M 85.9M 162M 11.04B 165M 1.1B 433M 5.5B 434M 425M 18.43B
Net income 137M 20.27M 17.62M 16.4M 15.06M 28.44M 1.94B 28.88M 193M 75.89M 963M 76.14M 74.47M 3.23B 174M 25.78M 22.41M 20.86M 19.15M 36.16M 2.46B 36.72M 246M 96.49M 1.23B 96.81M 94.68M 4.11B
Net Debt - -
Logo HitGen Inc.
HitGen Inc is a China-based company primarily engaged in the research, development and optimization of small molecule and nucleic acid-based new drug candidates using deoxyribonucleic acid (DNA) encoded chemical library (DEL) technology. Through the drug discovery and optimization platform, the Company provides clients with services such as screening and optimization of designated biological targets, customized DEL design and synthesis, synthesis and modification of certain designated compounds or nucleic acids and related biological evaluation. The Company is also engaged in the transfer of rights and interests in new drug research projects, capital operations and marketing activities. The Company primarily operates its businesses in the domestic market and overseas markets, including the United States, France, the United Kingdom and Japan.
Employees
546
Date Price Change Volume
26-07-31 CN¥27.61 +4.98% 14,677,839
26-07-30 CN¥26.30 -8.49% 15,580,603
26-07-29 CN¥28.74 +1.70% 11,975,464
26-07-28 CN¥28.26 -4.72% 13,843,607
26-07-27 CN¥29.66 +7.35% 21,360,625
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
27.61CNY
Average target price
31.60CNY
Spread / Average Target
+14.45%

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 688222 Stock